NCT03990961View on ClinicalTrials.gov

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Diffuse Large B Cell LymphomaLymphoma
Interventions
DRUG

Pembrolizumab

Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).

Trial Locations (1)

60637

The University of Chicago Medicine, Chicago

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Chicago

OTHER